Prostate-specific antigen (PSA) is the most accurate serum marker for cancer of the prostate (CAP). However, its sensitivity and specificity are suboptimal, especially at values ranging between 4.1 and 10.0ng/ml (monoclonal), because benign prostatic hypertrophy and hyperplasia (BPH) and CaP frequen
Prostate-specific antigen density — a reliable parameter for the detection of prostate cancer?
✍ Scribed by W. F. Thon; F. Gadban; M. C. Truss; M. Kuczyk; U. Hartmann; U. Jonas
- Publisher
- Springer-Verlag
- Year
- 1996
- Tongue
- English
- Weight
- 595 KB
- Volume
- 14
- Category
- Article
- ISSN
- 0724-4983
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Background. Prostate specific antigen (PSA) is useful as a tumor marker for monitoring patients with prostate cancer after definitive therapy. Limitations have been noted when PSA was used for the early detection of prostate cancer. The use of prostate specific antigen density [PSAD = PSA (ng/ml)/pr
## Abstract The aim of our study was to estimate uptake of prostate‐specific antigen (PSA) testing in an entire country, including time trends and geographical differences. Data from the Swedish Cancer Register on prostate cancer incidence between 1980 and 2007 and published data from the Gothenbur